MSN Labs enters into licence agreement with DRDE for COVID-19 drug 2-DG

Developed by DRDO, 2-DG has been granted permission by the Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, MSN Labs said in a statement.